Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

BACKGROUND: High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patien...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Lancet Oncol
Prif Awduron: Luen, Stephen J, Salgado, Roberto, Fox, Stephen, Savas, Peter, Eng-Wong, Jennifer, Clark, Emma, Kiermaier, Astrid, Swain, Sandra M, Baselga, Jose, Michiels, Stefan, Loi, Sherene
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5477653/
https://ncbi.nlm.nih.gov/pubmed/27964843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30631-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg